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Abstract
Background: The preferred chemotherapy method for gastric cancer continues to be matter of debate. We
performed a meta-analysis to comparing prognosis and safety between perioperative chemotherapy and
adjuvant chemotherapy to identify the better chemotherapy option for gastric cancer.
Methods: We searched the PubMed, EMBASE, Cochrane Library, and Ovid databases for eligible studies until
February 2016. The main endpoints were prognostic value (hazard ratio [HR] for overall survival [OS] and 1-, 2-, 3-, and
5-year survival rate), response rate of chemotherapy, radical resection rate, post-operative complication rate, and
adverse effects of chemotherapy.
Results: Five randomized controlled trials and six clinical controlled trials involving 1,240 patients were eligible
for analysis. Compared with the adjuvant chemotherapy group, the perioperative chemotherapy group had
significantly better prognosis (HR, 0.74; 95 % CI, 0.61 to 0.89; P < 0.01). The difference between the two groups
remained significant in the studies that used combination chemotherapy as the neoadjuvant chemotherapy
regimen (HR, 0.59; 95 % CI, 0.46 to 0.76; P < 0.01) but were not significant in the studies that used fluoropyrimidine
monotherapy (HR, 0.93; 95 % CI, 0.56 to 1.55; P = 0.84). Furthermore, the two groups showed no significant differences
in the post-operative complication rates (relative risk, 0.98; 95 % CI, 0.63 to 1.51; P = 0.91) or adverse effects of
chemotherapy (P > 0.05 for all adverse effects).
Conclusion: Perioperative chemotherapy showed improved survival compared to adjuvant chemotherapy for
gastric cancer. In addition, combination chemotherapy resulted in better survival compared to monotherapy in
the neoadjuvant chemotherapy regimens.
Keywords: Gastric cancer, Perioperative chemotherapy, Adjuvant chemotherapy, Overall survival, Combination
chemotherapy
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Background
Gastric cancer (GC) is the fourth most common cancer
and the second leading cause of cancer-related deaths
worldwide [1, 2]. To date, surgery is the only curative
treatment for GC. However, the results are still unsatis-
factory, owing to the high rate of metastasis and re-
lapse [1, 3].
Chemotherapy together with surgery has shown promis-
ing results. For instance, a randomized controlled trial
conducted by Cunningham et al. [4] showed that peri-
operative chemotherapy (PC) could result in better sur-
vival than surgery alone. Similarly, Bang et al. [5] showed
that adjuvant chemotherapy (AC) could improve survival
over surgery alone. However, the method of delivery of
chemotherapy for GC is still a matter of debate. PC con-
sists of preoperative (neoadjuvant) chemotherapy and
postoperative chemotherapy, and is provided as standard
of care in NCCN guideline for GC. At the same time, the
application of AC is limited to situations where neoadju-
vant therapy had not been given prior to surgery [6]. How-
ever chemotherapy given prior to surgery may reduce
tumor burden and eradicate micrometastatic foci outside
the surgical field [7, 8]. Several studies have emphasized
the survival benefits of PC to the patients [9, 10]. How-
ever, chemortherapy given prior to surgery can cause
fibrosis and tissue edema, which may cause difficulties
during surgery [11], causing adverse effects to the patients
[12, 13]. Therefore, we performed a meta-analysis to com-
pare the prognostic value, side effects, and post-operative
complications of PC and AC in patients with GC.
Methods
Search strategy
Studies were selected by searching major medical data-
bases (PubMed, EMBASE, Cochrane Library, and Ovid)
for all articles published until February 1, 2016. We used
the following keywords: “neoadjuvant”, “preoperative”,
“perioperative”, “chemotherapy”, “stomach neoplasm”,
“gastric cancer”, and “gastrectomy” Then, we narrowed
the search by browsing the abstracts, methods, and ref-
erences of the articles retrieved.
Inclusion and exclusion criteria
The studies that met the following criteria were in-
cluded: (i) publications that compared PC with AC in
patients with GC undergoing surgery; (ii) the full text of
the articles was available, with a clear description of the
chemotherapy regimens used in the study; (iii) at least
one of the outcome measures mentioned below was re-
ported or could be calculated from the data provided.
In cases of overlap between authors or institutions, only
the higher-quality or more recent study was selected.
Studies were excluded for the following reasons: (i) PC
and AC were not compared in the patients with GC;
(ii) post-operative chemotherapy was not applied in ei-
ther the PC or AC groups; (iii) radiotherapy was part of
treatment.
Outcome measures, data extraction, and assessment of
the risk of bias
The primary outcomes were prognostic value (hazard
ratio [HR] for overall survival [OS] and 1-, 2-, 3-, and
5-year survival rate), response rate of chemotherapy
(response rate: complete response [CR] or partial re-
sponse [PR] after chemotherapy), radical resection rate;
total post-operative complication rate (defined on the
basis of the system for reporting complications estab-
lished by the Memorial Sloan-Kettering Cancer Center
[14]), and the adverse effects of chemotherapy. Two au-
thors independently extracted data from full-text arti-
cles using a unified datasheet. Randomized controlled
trials (RCTs) were evaluated using the Jadad Composite
Scale (JCS), wherein high-quality trials should score ≥ 3
of a maximum possible score of 5. Controlled clinical
trials (CCTs) were evaluated using the Newcastle–
Ottawa Scale [15], wherein high-quality trials should
score ≥ 7 of a maximum possible score of 9, and
moderate-quality trials should score ≥ 5. Disagreements
were presented to a third author and resolved by dis-
cussions among the investigators.
Statistical analysis
This meta-analysis was conducted using RevMan soft-
ware version 5.2 (Cochrane Collaboration). The risk ra-
tio (RR) and HR were used to evaluate the prognostic
effect. If the HR and its variance were not reported dir-
ectly in the original study, these values were calculated
using a software designed by Tierney et al. [16]. For
HR, we performed subgroup analysis based on available
method, such as study design, NAC regimen, et al. In
addition, the RR was used to analyze other discontinu-
ous variables. Both ratios were reported with 95 % con-
fidence intervals (CIs). Heterogeneity was determined
using the χ2 test or Cochran Q test. I2 was used to
quantify heterogeneity. P < 0.10 and I2 > 50 % indicated
significant heterogeneity. The inverse variance method
with a fixed-effects model was applied when heterogen-
eity was not found, whereas the random-effects model
was used when heterogeneity was found. Publication
bias was tested using funnel plots. P < 0.05 was consid-
ered significant when measuring the effect sizes. This
manuscript reporting adheres to PRISMA guidelines
for reporting systematic reviews and meta-analyses.
Results
Eligible studies
The search for the aforementioned keywords allowed
the identification of 4538 articles. Five RCTs [17–21]
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and six CCTs [9, 11, 22–25] were considered eligible for
this meta-analysis (Fig. 1). The analyses included 1240
patients who were in the PC group (n = 557) or in the
AC group (n = 683). The detailed characteristics of the
patients are listed in Table 1 and Additional file 1. Four
RCTs scored 3 in the JCS, indicating that they were
high-quality studies (Table 2). Three CCTs scored 6
(moderate-quality study) on the Newcastle–Ottawa scale
and 3 CCTs scored 7 (high-quality study) (Table 3).
Hazard ratio for the overall survival
Nine [9, 17–22, 24, 25] out of eleven studies (5 RCTs
and 4 CCTs) evaluated provided effective data for the
calculation of the HR for OS. Compared with the AC
group, the PC group had significantly better prognosis
(HR, 0.74; 95 % CI, 0.61 to 0.89; P < 0.01, Fig. 2a-c). The
difference between the two groups remained significant
subgroup analysis that only consisted of RCTs (HR, 0.74;
95 % CI, 0.60 to 0.93; P = 0.01) (Fig. 2a).
We also performed a subgroup analysis examining
the nine studies divided into two subgroups: the fluoro-
pyrimidine monotherapy subgroup and combination
chemotherapy subgroup (Fig. 2b). PC did not demon-
strate improved prognosis in the fluoropyrimidine
monotherapy subgroup (HR, 0.93; 95 % CI, 0.56 to
1.55; P = 0.84) but did show improved prognosis in the
combination chemotherapy subgroup (HR, 0.59; 95 %
CI, 0.46 to 0.76; P < 0.01).
We also performed a subgroup analysis considering
the study locations (Fig. 2c). Five where Chinese studies
and four Japanese studies. PC resulted in significantly
better prognosis in the Chinese studies (HR, 0.61; 95 %
CI, 0.47 to 0.80; P < 0.01) but not in the Japanese studies
(HR, 0.88; 95 % CI, 0.68 to 1.13; P = 0.30).
1-, 2-, 3-, 5-year survival rates
Nine [9, 17–22, 24, 25], nine [9, 17–22, 24, 25], seven
[9, 17, 18, 20–22, 25], six [9, 18, 20, 21, 23, 25] studies
reported 1-, 2-, 3-, 5- year survival rates, respectively.
There were no significant differences in the 1- and 2-
year survival rates between the two study groups (1-year
survival rate: RR, 0.81; 95 % CI, 0.60 to 1.09; P = 0.17,
Additional file 2A; 2-year survival rate: RR, 0.90; 95 % CI,
0.77 to 1.04; P = 0.15, Additional file 2B). However, the PC
group showed significantly better prognosis for 3- and 5-
year survival rates (3-year survival rate: RR, 0.80; 95 % CI,
0.67 to 0.96; P = 0.01, Additional file 2C; 5-year survival
rate: RR, 0.77; 95 % CI, 0.64 to 0.92; P < 0.01, Additional
file 2D).
Response rate to neoadjuvant chemotherapy
Eight studies [9, 11, 17–20, 22, 24] reported the response
rates to NAC in 358 patients. The response rate ranged
between 33.3 and 70.0 %. In total, 199 patients achieved
CR or PR. The overall response rate was 55.6 %.
Radical resection rate
Seven studies [9, 11, 17–19, 22, 24] reported the radical
resection rate. A total of 218 out of 265 patients (82 %)
in the PC group and 218 out of 292 (74 %) patients in
the AC group received radical resection. Although no
significant difference was observed, the PC group
showed a trend towards a higher radical resection rate
(RR, 1.10; 95 % CI, 0.96 to 1.27; P = 0.17, Fig. 3a).
Total post-operative complication rate
Five studies [9, 11, 19, 22, 24] reported the prevalence of
complications. A total of 31 out of the 213 patients in
the PC group and 37 out of 243 patients in the AC
group suffered postoperative complications. There was
Fig. 1 Flow chart of articles selection
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Table 1 Main characteristics of including studies
study year place design Patients number follow-up Regimena Age Sex (male/female)
PC AC PC group AC group PC AC PC NC
preoperative postoperative
Yonemura 1993 Japan RCT 29 26 3 years PMUE PMUE PMUE 61.4 ± 8.34 56.4 ± 9.6 21/8 20/6
Kobayashi 2000 Japan RCT 91 80 5 years 5′-DFUR 5′-DFUR + MMC 5′-DFUR + MMC 57.8 60.2 65/26 55/25
Nio 2004 Japan RCT 102 193 7 years UFT UFT or FPEPIR + UFT UFT or FPEPIR + UFT 63.5 ± 11.9 65.3 ± 11.5 70/32 141/52
Qu 2010 China RCT 39 39 ≥2 years PTX + FOLFOX4 PTX + FOLFOX4 or ECF PTX + FOLFOX4 NA NA 26/13 22/17
X.Sun 2011 China RCT 29 26 3 years DCF DCF DCF 52.6 (33–72) 37/18
Z.Sun 2014 China CCT 23 35 3 years FOLFOX4 FOLFOX FOLFOX 58 (34–79) 57 (31–80) 15/8 22/13
Feng 2015 China CCT 80 90 Till discharge SOX SOX SOX 61 (21–74) 59 (29–82) 63/17 71/19
Li 2012 China CCT 33 37 ≥ 5 years FOLFOX FOLFOX FOLFOX 65 (41–75) 61 (27–78) 23/10 30/7
J.Zhang 2012 China CCT 38 42 5 years mFOLFOX7 mFOLFOX7 or mECF mFOLFOX7 NA NA 22/16 26/16
Nishioka 1982 Japan CCT 64 59 5 years 5-FU 5-FU and MMP 5-FU and MMP NA NA NA NA
C.Zhang 2004 China CCT 29 56 5 years FAP or FMP FAP or FMP FAP or FMP 54.9 ± 12.9 69/22
PC perioperative chemotherapy, AC adjuvant chemotherapy, RCT randomized controlled trails, CCT clinical controlled trails











no significant difference between two groups (RR, 0.98;
95 % CI, 0.63 to 1.51; P = 0.91, Fig. 3b).
Adverse effects of chemotherapy
Three studies [17, 19, 24] reported adverse effects of
chemotherapy in detail. Our meta-analysis indicated
that all the adverse effects (including nausea and
vomit, gastrointestinal problem, liver toxicity, neuro-
logic effects, leukopenia, thrombocytopenia, and neu-
tropenia) were not significantly different between the
two study groups (P > 0.05 for all the comparisons,
Additional file 3).
Publication bias
A funnel-plot analysis was performed to determine the
publication bias on the basis of the measurement of HR
for OS (Fig. 4). The analysis indicated that all the stud-
ies were within the funnel plot and were distributed
symmetrically.
Discussion
Two methods of chemotherapy delivery, perioperative
chemotherapy (PC) and adjuvant chemotherapy (AC)
are widely used. However, there is no high level evidence
comparing the prognosis and safety between PC and
AC. Our meta-analysis that synthesized the results of
several smaller studies showed that PC was superior to
AC when considering the HR for OS and the 3–, 5-year
survival rates. This result indicates that the addition of
chemotherapy prior to surgery could provide additional
benefits over chemotherapy provided after surgery alone.
This may occur because of the effects of NAC in redu-
cing tumor burden and eradicating micrometastatic foci
[8]. In this meta-analysis, the response rate to NAC
reached 55.6 %. In addition, the radical resection rate
was relatively higher in the PC group.
Fluoropyrimidine is the most common and widely ac-
cepted chemotherapy drug for GC [26, 27]. However,
combination chemotherapy that includes fluoropyrimi-
dine rather than fluoropyrimidine alone is used and rec-
ommended by most professionals [4, 28–31]. In our
meta-analysis, PC failed to show significant benefits
compared with AC in the fluoropyrimidine monotherapy
subgroup. However, a significant difference was observed
between the two groups in the combination chemother-
apy subgroup. This suggests that combination chemo-
therapy is a better option for NAC in GC and provides
significant advantage in relation to fluoropyrimidine
monotherapy.
The stage of cancer is another important issue when
choosing the treatment method. In the NCCN guide-
line, for early-stage GC, PC is not routinely recom-
mended [6]. To better understand this issue, we
considered the tumor stages reported in the studies in-
cluded in this meta-analysis. In addition, in almost all
the studies included, the majority, if not all, of the pa-
tients were at advanced stages. However, the RCT by
Nio et al. [20] was an exception. Of the 295 patients
evaluated in the RCT, 170 patients were stage 1, and
this subgroup failed to show any advantage of PC over
AC. On the other hand, when we redid the meta-
analysis excluding stage 1 patients and only including
stage 2 and 3 patients, the survival benefits of PC be-
came more significant (HR 0.68; 95 % CI, 0.56 to 0.83;
Table 3 The risk of bias of CCTS (NOS)
Reference Selection Comparability Outcome Total Quality
REC SNEC AE DO SC AF AO FU FUO
C.Zhang 1 0 1 1 0 0 1 1 1 6 Moderate
Z.Sun 1 1 1 1 0 0 1 1 1 7 High
Feng 1 1 1 1 0 0 1 0 1 6 Moderate
Li 1 1 1 1 0 0 1 0 1 6 Moderate
J.Zhang 1 1 1 1 0 0 1 1 1 7 High
Nishioka 1 1 1 1 0 0 1 1 1 7 High
REC representativeness of the exposed cohort, SNEC selection of the non-exposed cohort, AE ascertainment of exposure, DO demonstration that outcome of
interest was not present at start of study, SC study controls for age, sex, AF study controls for any additional factors, AO assessment of outcome, FU follow-up
long enough for outcomes to occur, FUO adequacy of follow-up of cohorts
Table 2 The risk of bias of RCTS (Jadad scale)





Yonemura 2 0 0 2 Moderate
Kobayashi 2 0 1 3 High
Nio 2 0 1 3 High
Qu 2 0 1 3 High
X.Sun 2 0 1 3 High
Randomization: randomization was described with appropriate method- 2 score,
randomization was described without appropriate method- 1 score, no
randomization- 0 score
Blinding: blinding was performed on all doctors and patients- 2 score, blinding
was partially performed on doctors and patients- 1 score, no blinding- 0 score
Withdraw and dropout: the reason of withdraw and dropout was described- 1
score, the reason of withdraw and dropout was not described- 0 score
Quality: High-quality trials should score ≥ 3. moderate-quality trials
should score ≥ 2
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P < 0.01). Therefore, the conclusion that “perioperative
chemotherapy was superior to adjuvant chemotherapy
in the survival benefits” seems to be more suitable for
advanced GC.
The results of two large European RCTs [4, 32], which
compared PC and surgery alone, established PC as an-
other alternative option for GC. However, no European
studies have compared PC and AC. Furthermore, all 11
studies included in this meta-analysis were from Asian
countries (China and Japan). We performed a subgroup
analysis for these two countries and the results indicated
that the Chinese group showed an advantage compared
with the Japanese group. This observation may be ex-
plained by the fact that Nio et al. [20] included many
early-stage patients and most Japanese studies used
fluoropyrimidine monotherapy as their NAC method.
This suggests that Japanese groups should give more
consideration to the use of combination chemotherapy,
especially in the pre-operative setting.
Another potential advantage of perioperative chemo-
therapy is that it increases the likelihood that patients
will receive at least part of their planned systemic
chemotherapy regimen. For example, Yonemura [17] re-
ported that patients in PC group received relative more
courses of regimen in fact. In that study, patients in PC
and AC received an average of 2.9 and 2.3 courses of
regimen respectively. However, this issue is not reported
by the others studies. We believe that studies should pay
more attention to this matter in the future.
Safety is always of the utmost concern in clinical prac-
tice. Because fibrosis, tissue edema and toxicity may re-
sult from chemotherapy [11, 33], there is a concern that
the addition of chemotherapy prior to surgery may in-
crease the risk during surgery as well as increase compli-
cation rates and adverse effects [34]. In our study, the
complication rates and adverse effects during PC were
similar to those of AC. Postoperative complication rates
were also consistent with the studies that evaluated the
effects of NAC (without the restrictions of AC adminis-
tration) [35, 36]. However, only three studies reported
adverse effects, and these studies were not enough to
draw a solid conclusion. More investigations are needed
to evaluate the side effects of PC.
To the best of our knowledge, this is the first meta-
analysis that compares PC with AC in GC. In our
meta-analysis, we included 11 studies, five of which
were RCTs, and found that PC was superior to AC in
the survival effects without compromising safety. In
addition, combination chemotherapy was a better op-
tion in the pre-operative setting over monotherapy. A
subgroup analysis involving three studies [10] in a pre-
vious meta-analysis evaluated the effects of NAC in GC
and found similar survival benefits. Several limitations
of our study should be considered. First, we included
Fig. 3 a Meta-analysis of Hazard ratio for radical resection rate; b Meta-analysis of postoperative complication rate
Fig. 2 a-c Meta-analysis of hazard ratio for overall survival subgrouped by (a) RCT or CCT, b neoadjuvant chemotherapy regimen, (c) where the
study from
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some retrospective studies, which may influence the
statistical power. Second, all studies were from Asia
and limits its generalizability for GC patients world-
wide. Third, only a few studies compared the adverse
effects of chemotherapy, which did not allow us to
draw conclusions about the safety of PC.
Conclusion
Perioperative chemotherapy provides a survival advan-
tage over adjuvant chemotherapy for GC patients, espe-
cially for the patients with advanced GC. In addition,
combination chemotherapy is a better option for neo-
adjuvant chemotherapy regimen over monotherapy.
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Meta-analysis of 5 year survival rate. (TIF 457 kb)
Additional file 3: meta-analysis of chemotherapy adverse effects. (A)
Nausea and vomit, (B) gastrointestinal problem, (C) liver toxicity, (D)
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